• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • ScFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing
  • CAR Cell In Vitro Assay
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trial
  • One-Stop Canine CAR-T Therapy Development
  • One-Stop mRNA CAR-T Therapy Development
  • TRAC-CAR-T Cell Development
  • Modular CAR-T Cell Generation
  • One-Stop Silence™ CAR-T Cell Development
  • Vaccine Boosting CAR-T Cell Therapy
  • STAb-T Cell Therapy Development
  • CAR-T Therapy Development in the Non-Cancer Field
  • Anti-HIV CAR Cell Therapy Development
  • T Cell Activity Modulator Discovery
  • T Cell Programming
  • Virus Specific T Cell (VST) Development
  • Antibody-Coupled T Cell Receptor (ACTR) Development
  • Organoid-induced hPSC-original T Cell Differentiation
  • γδ T Cell Engineering
  • CAR-T CDMO
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Clinical Application
  • TCR Analysis
  • TCR Tetramerization Construction
  • ScFv-TCR T Cell Therapy Development
  • AbTCR Development
  • Bispecific TCR Development
  • CER Development
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-Stop CAR-NKT Therapy Development
  • One-Stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-Stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering
  • NK Cell Expansion
• One-Stop CAR-B Therapy Development
• One-Stop CAR-Monocyte Therapy Development
• One-Stop Cytokine Release Syndrome (CRS) Management
• TCR-Like Antibody Development
  • MHC/Peptide Complex Production
  • TCR-Like Antibody Discovery
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction & Evaluation
• In Vivo Cell Engineering Development
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• One-Stop Allogeneic Cell Therapy Development
  • Allogeneic CAR-T Therapy Development
  • Allogeneic TCR-T Therapy Development
  • Allogeneic CAR-NK Therapy Development
  • Allogeneic CAR/TCR Cell Design & Engineering
  • Other Allogeneic Cell Therapy Development
• TCR/CAR/Antigen-Engineered Tregs Development
  • CAR-Treg Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
  • Dendritic Cell Vaccine Development
• Immune Genotyping
  • HLA Typing
  • KIR Typing
  • HLA Testing
  • Dog DLA Genotyping
  • Guinea Pig GPLA Genotyping
  • Mouse H2 Genotyping
  • Rabbit RLA Genotyping
  • Rat RT1 Genotyping
  • Rhesus Macaque MHC Genotyping
• Other Services
  • Tumor-infiltrating Lymphocyte-based Antibody Discovery

CRS In Vitro Assay Services

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Based on the unrivaled expertise and experience in immunotherapy discovery and development, Creative Biolabs independently has developed a novel in vitro assay service of CRS for global clients to speed up the development of immunotherapy projects.

The Basis of In Vitro Assay Service of CRS

In recent years, immune-oncology therapies such as checkpoint inhibitors, bi-specific antibodies, and CAR-T cell therapies have brought a great promise for cancer therapy. However, they can have very severe adverse effects such as cytokine release syndrome (CRS). Currently, various in vitro assay formats can be considered when evaluating the potential for cytokine release and cytotoxicity. Despite the challenges of interpreting cytokine release assay (CRA) data, cytokine release assessment has become a growing useful tool for predicting the safety of immunotherapies. The positive results of cytokine level and cytotoxicity in vitro can provide the theoretical basis for determining the starting dose of therapies. Therefore, the development of a well-established assay or one that can reliably predict the potential of immunotherapy to initiate cytokine release syndrome is still urgently needed.

CBL's In Vitro Assay Service of CRS

Creative Biolabs can provide both in vitro cytokine release assay service and in vitro cytotoxicity analysis service. What is more, the diversity of modalities of action of specific drugs in induction cytokine release may need the availability of adaptive or flexible in vitro assay platforms to identify potential clinical risk for specific therapeutic candidates. Creative Biolabs will optimize the experimental conditions as much as possible according to the requirements of your project and provide our clients with appropriate customized services.

Working with Creative Biolabs

With profound expertise and state-of-the-art technology platforms, we are committed to providing tailored services to each project to ensure that the objectives are met or exceeded. For further details, please don't hesitate to contact us and see how we can help you reach your clinical vision.

References

1. Grimaldi, C., et al. Cytokine release: workshop proceedings on the state-of-the-science, current challenges, and future directions. Cytokine, (2016): 85, 101-108.
2. Draheim, Kyle, et al. An in vivo model to evaluate donor-dependent cytokine release in response to single-agent or combination immune-oncology therapies. (2020): 3114-3114.
3. Shimabukuro-Vornhagen, A., et al. Cytokine release syndrome. Journal for immunotherapy of cancer, (2018): 6(1), 1-14.